-59%

est. 2Y upside i

HealthcareSeries C

Rank

#2113

Sector

Health Care Technology

Est. Liquidity

~3Y

Data Quality

Data: Low

Nym presents a moderate upside opportunity for a job seeker, operating in a rapidly growing AI medical coding market projected to reach over $10B by 2034.

Last updated: March 10, 2026

Bull (27%)+150%

Nym's proprietary AI and Clinical Language Understanding technology achieves widespread adoption across major health systems, expanding beyond its current six specialties and capturing significant market share from legacy manual coding and less sophisticated automated solutions. This drives revenue to over $200M by 2028, justifying a $1.5B+ valuation at a 7.5x revenue multiple, well above the estimated current $600M.

Base (42%)+50%

Nym continues to grow steadily, securing new customer wins and expanding its platform within existing clients, but faces increasing competition from established RCM players and new entrants. Revenue reaches approximately $110M by 2028, leading to a $900M valuation at a 8.2x revenue multiple, representing a moderate upside from the current valuation.

Bear (31%)-50%

Dominant EHR vendors or large healthcare technology incumbents like R1 RCM develop or acquire competing autonomous coding solutions, commoditizing Nym's core offering and slowing its growth. Regulatory changes or slower-than-expected adoption of AI in healthcare further hinder expansion, causing revenue to stagnate around $75M and leading to a down round or exit at $300M, significantly eroding common stock value given the preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $94.5M in liquidation preferences ahead of common stock, representing 15.75% of the estimated $600M current valuation.

Dilution Risk

moderate

As a Series C company, Nym will likely require 1-2 more funding rounds before a potential IPO or acquisition, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Nym's equity at this stage.

Questions to Ask at the Interview

Strategic questions based on Nym's data — designed to show you've done your homework.

  • 1

    “Given the strong market growth in AI medical coding, how does Nym plan to differentiate and maintain its competitive moat against larger incumbents like R1 RCM and potential entries from major EHR vendors like Epic?”

  • 2

    “Nym has processed over 6 million medical records in the past year. What is the strategy for scaling this volume significantly while maintaining the reported 95%+ accuracy and ensuring compliance with evolving healthcare regulations?”

  • 3

    “With total funding of $94.5M and a recent Series C round, how is the company thinking about a liquidity event timeline for employees, and what are the key milestones Nym aims to achieve in the next 2-3 years to get there?”

Community

Valuation Sentiment

Our model estimates -59% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.